Reactome | IFNAR2:JAK1:STAT2 binds type 1 interferon analogs

Schema > Reaction > Entries

IFNAR2:JAK1:STAT2 binds type 1 interferon analogs Show undefined attributes

authored	[InstanceEdit:9696165] Jassal, Bijay, 2020-07-20
category	binding
compartment	[Compartment:984] extracellular region [Compartment:876] plasma membrane
created	[InstanceEdit:9696165] Jassal, Bijay, 2020-07-20
dbId	9696179
displayName	IFNAR2:JAK1:STAT2 binds type 1 interferon analogs
edited	[InstanceEdit:9696165] Jassal, Bijay, 2020-07-20 [InstanceEdit:9773839] Matthews, Lisa, 2022-05-10
eventOf	[Pathway:R-HSA-909733] Interferon alpha/beta signaling - Homo sapiens [Pathway:R-HSA-9679191] Potential therapeutics for SARS - Homo sapiens
input	[Complex:R-HSA-918193] IFNAR2:JAK1:STAT2 [plasma membrane] [DefinedSet:R-HSA-9696187] type 1 interferon analogs [extracellular region]
isChimeric	false
isInDisease	false
isInferred	false
literatureReference	[LiteratureReference:9696216] Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis [LiteratureReference:9696191] Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study [LiteratureReference:9696199] Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome [LiteratureReference:9734418] Interferon ?-1b in treatment of severe COVID-19: A randomized clinical trial [LiteratureReference:9734400] Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial [LiteratureReference:9696152] Efficacy and safety of interferon ?-1a in treatment of severe COVID-19: A randomized clinical trial [LiteratureReference:9734375] Interferon-?2b Treatment for COVID-19 [LiteratureReference:9734378] Corrigendum: Interferon-?2b Treatment for COVID-19 [LiteratureReference:9734392] Interferon-?2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities [LiteratureReference:9734374] The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19 [LiteratureReference:9734399] SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial
maxDepth	1
modified	[InstanceEdit:10732209] Weiser, Joel, 2026-03-16
name	IFNAR2:JAK1:STAT2 binds type 1 interferon analogs
orthologousEvent	[Reaction:R-MMU-9696179] IFNAR2:JAK1:STAT2 binds type 1 interferon analogs - Mus musculus [Reaction:R-GGA-9696179] IFNAR2:JAK1:STAT2 binds type 1 interferon analogs - Gallus gallus [Reaction:R-XTR-9696179] IFNAR2:JAK1:STAT2 binds type 1 interferon analogs - Xenopus tropicalis [Reaction:R-SSC-9696179] IFNAR2:JAK1:STAT2 binds type 1 interferon analogs - Sus scrofa [Reaction:R-BTA-9696179] IFNAR2:JAK1:STAT2 binds type 1 interferon analogs - Bos taurus [Reaction:R-CFA-9696179] IFNAR2:JAK1:STAT2 binds type 1 interferon analogs - Canis familiaris [Reaction:R-RNO-9696179] IFNAR2:JAK1:STAT2 binds type 1 interferon analogs - Rattus norvegicus
output	[Complex:R-HSA-9696161] IFNAR2:JAK1:STAT2:type 1 interferon analogs [plasma membrane]
releaseDate	2022-06-09
reviewStatus	[ReviewStatus:9821382] five stars
reviewed	[InstanceEdit:9767610] Huddart, Rachel, 2022-03-01
revised	[InstanceEdit:9734417] Stephan, Ralf, 2021-06-16
schemaClass	Reaction
species	[Species:48887] Homo sapiens
stId	R-HSA-9696179
summation	[Summation:9696206] Natural ligands of the IFNAR1/2 receptor include interferon ...

Referrals

(hasEvent)

Cite Us!